Cameroon received a gift of 200,000 doses of China's Sinopharm vaccine against Covid-19 on Sunday, state television reported.

The vaccine will be used in the first phase of the central African country's inoculation campaign.

Health Minister Malachie Manaouda urged Cameroonians to get the jab, "especially priority targets", in a statement dated Friday.

The country of around 26 million people is one of the hardest hit on the African continent, with 61,700 cases and 919 deaths recorded.

Neighbours Equatorial Guinea and Gabon have already begun inoculation campaigns using the Sinopharm vaccine.

China said in December that the vaccine is 79 percent effective, without publishing the results of its clinical trials.

Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola

Tweet

Thanks for being here; We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain. With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor $5 Billed Once credit card or paypal		SpaceDaily Monthly Supporter $5 Billed Monthly paypal only

China mulls mixing vaccines to improve efficacy of jabs
Beijing (AFP) April 11, 2021
China is considering the mixing of different Covid-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert has told a conference. Authorities have to "consider ways to solve the issue that efficacy rates of existing vaccines are not high", Chinese media outlet The Paper reported, citing Gao Fu, the head of the Center for Disease Control and Prevention. His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy ... read more